Crosstalk between coagulation and inflammation during Dengue virus infection

Summary

Dengue fever is the most prevalent viral disease transmitted by vectors (Aedes aegypti, Aedes albopictus) in worldwide. More than 100 million cases occur annually with a mortality rate of 5% and no safe vaccine is available. The pathogenesis of Dengue, where host and viral factors participate in the establishment of Dengue haemorrhagic fever (DHF) and Dengue shock syndrome (DSS) remains unresolved. Clinical observations have revealed significant abnormalities in coagulation and inflammation systems, with increased levels of tissue factor (TF) and the chemokine IL-8, correlating with the severity of the disease and implicating damage to endothelial vascular cells (EVC). Here we present novel insights concerning the crosstalk between the regulatory signaling pathways of the coagulation-inflammation processes, during Dengue virus (DV) infection of EVC. We found that DV up-regulates Protease Activated receptor type-1 (inflammation) and TF (coagulation) receptors, via the phosphorylation of p38 and ERK1/2 MAPKs, which favor the activation of NF-κB transcription factor. This induces pro-inflammatory (IL-8) or pro-adhesive (VCAM-1) gene expression which may lead to EVC activation. The elucidation of the basic principles that signal these processes has important implications for the design of new therapeutic strategies for DHF/DSS.

keywords

Dengue virus - tissue factor - PAR-1 - endothelial cell - crosstalk - coagulation-inflammation

• References

• 1 Gubler DJ. Dengue and Dengue hemorrhagic fever. Clin Microbiol 1998; 11: 480-496.
• 2 Gubler DJ. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle?. Comp Immunol Microbiol Infect Dis 2004; 27: 319-330.
• 3 Westaway EG, Blok J. Taxonomy and evolutionary relationships of flaviviruses. Dengue and Dengue Hemorrhagic Fever.. London, United Kingdom: CAB International Press; 1997: 147-173.
• 4 Hasltead SB. Pathogenesis of dengue: challenge to molecular biology. Science 1988; 239: 476-481.
• 5 Riewald M, Ruf W. Science review: role of coagulation protease cascades in sepsis. Crit Care 2003; 7: 123-129.
• 6 Strukova S. Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation- dependent thrombosis. Front in Biosci 2006; 11: 59-80.
• 7 Schnittler HJ, Feldmann H. Viral hemorrhagic fever a vascular disease?. Thromb Haemost 2003; 89: 967-972.
• 8 Wiiger MT, Prydz H. The changing faces of tissue factor biology. Thromb Haemost 2007; 98: 38-42.
• 9 Morrissey JH. Tissue factor: An enzyme cofactor and a true receptor. Thromb Haemost 2001; 86: 66-74.
• 10 Siegbahn A, Johnell M, Sorensen BB. et al. Regulation of chemotaxis by the cytoplasmic domain of tissue factor. Thromb Haemost 2005; 93: 27-34.
• 11 Niessen F, Schaffner F, Furlan-Freguia Ch. et al. Dendritic cell PAR1-SIP3 signalling couples coagulation and inflammation. Nature Letters. 2008: 1-5.
• 12 Schouten M, Joost Wiersinga W, Levi M. et al. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol. 2008: 83
• 13 Suharti C, van Gorp ECM, Setiati TE. et al. The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome. Thromb Haemost 2002; 87: 42-46.
• 14 Welty-Wolf KE, Carraway MS, Ortel TL. et al. Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol 2006; 290: L21-L31.
• 15 Geisbert TW, Hensley LE, Jahrling PB. et al. Treatment of ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003; 362: 1953-1958.
• 16 Hensley LE, Geisbert TW. The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates. Thromb Haemost 2005; 94: 254-261.
• 17 Pawlinski R, Pedersen B, Erlich J. et al. Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. Thromb Haemost 2004; 92: 444-450.
• 18 Sosothikul D, Seksarn P, Pongsewalak S. et al. Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection. Thromb Haemost 2007; 97: 627-634.
• 19 Sánchez JI, Ruiz BH. A single nucleotide change in the E protein gene of dengue virus 2 mexican strain affects neurovirulence in mice. J Gen Virol 1996; 77: 2541-2545.
• 20 Olsen E. Culturing of human umbilical vein and dermal microvascular endothelial cells. Cell Biology: A Laboratory Handbook.. Academic Press Inc; 1994: 142-147.
• 21 Eckels KH, Brandt WE, Harrison VR. et al. Isolation of a temperature-sensitive dengue 2 virus under conditions suitable for vaccine development. Infect Immun 1976; 14: 1221-1227.
• 22 Kittigul L, Temprom W, Sujirarat D. et al. Determination of tumor necrosis factor-alpha levels in dengue virus infected patients by sensitive biotin-streptavidin enzyme-linked immunoabsorbent assay. J Virol Methods 2000; 90: 51-57.
• 23 Huang YT, Pan SL, Guh JH. et al. YC-1 Supresses constitutive nuclear factor-kB activation and induces apoptosis in human prostate cancer cells. Mol Cancer Ther 2005; 4: 1628-1635.
• 24 Bonner SM, OSullivan MA. Endothelial cell monolayers as a model system to investigate dengue shock syndrome. J Virol Methods 1998; 71: 159-167.
• 25 Koraka P, Murgue B, Deparis X. et al. Elevation of soluble VCAM-1 plasma levels in children with acute dengue virus infection of varying severity. J Med Virol 2004; 72: 445-450.
• 26 Raghupathy R, Chaturvedi UC, Al-Sayer H. et al. Elevated levels of IL-8 in dengue hemorrhagic fever. J Med Virol 1998; 56: 280-285.
• 27 Chiang ET, Persaud D, Kulkarni S. et al. Bluetongue virus and double-stranded RNA increase human vascular permeability: role of p38 MAPK. J Clin Immunol 2006; 26: 406-416.
• 28 Borbiev T, Birukova A, Liu F. et al. p38 MAP kinase- dependent regulation of endothelial cell permeability. Am J Physiol Lung Cell Mol Physiol 2004; 287: L911-L918.
• 29 Rahman A, True AL, Anwar KN. et al. Gαq and Gγq regulate PAR-1 signaling of thrombin-induced NF-κB activation and ICAM-1 transcription in endothelial cells. Circ Res 2002; 91: 398-405.
• 30 Flower DR. Modelling G-protein-coupled-receptors for drug design. Biochim Biophys Acta 1999; 14122: 207-234.
• 31 Abraham E, Reinhart K, Opal S. et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. J Am Med Assoc 2003; 290: 238-247.